Cedazuridine/地西他滨:从临床前到临床开发在髓系恶性肿瘤中的应用
本综述聚焦于DNA甲基转移酶抑制剂(HMA)在MDS/CMML治疗中的作用,回顾了cedazuridine/地西他滨(C-DEC)的临床前与临床开发历程。临床前研究显示C-DEC的药代与药效学特征与静脉地西他滨相近,早期临床试验确定口服地西他滨35 mg联合cedazuridine 100 mg为推荐2期剂量。2期数据证实C-DEC与静脉地西他滨生物等效,3期试验显示相似结果并促成FDA批准用于中/高危MDS和CMML。
要点
- 口服HMA因胞苷脱氨酶(CDA)快速代谢导致生物利用度差,cedazuridine作为CDA抑制剂可改善口服地西他滨暴露。
- 口服地西他滨35 mg联合cedazuridine 100 mg被确立为推荐2期剂量。
- 2期和3期试验证实C-DEC与静脉地西他滨生物等效,FDA已批准用于中/高危MDS和CMML。
核心结论
- C-DEC口服组合在MDS/CMML中展现出与静脉地西他滨相当的药代动力学和生物等效性,并获得FDA批准用于中/高危MDS和CMML。
研究设计与样本
- 本综述总结了HMA在MDS/CMML中的当前作用,并回顾了C-DEC从临床前到临床(包括早期试验、2期和3期试验)的开发过程。
主要发现
- 临床前研究显示C-DEC的药代动力学和药效学特征与静脉地西他滨相近。
- 早期临床试验确定口服地西他滨35 mg联合cedazuridine 100 mg为推荐2期剂量。
- 2期数据证实C-DEC与静脉地西他滨生物等效,3期试验显示相似结果。
关键数值与推荐
- 口服地西他滨35 mg联合cedazuridine 100 mg为推荐2期剂量。
- FDA批准C-DEC用于中/高危MDS和CMML。
临床怎么用
- C-DEC可作为中/高危MDS和CMML患者的一种口服HMA治疗选择。
- 口服HMA可能改变髓系恶性肿瘤的治疗模式,值得进一步研究其潜在角色。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the US Food and Drug Administration (FDA) approvals of parenteral decitabine and azacitidine, DNA methyltransferase inhibitors, otherwise referred to as DNA hypomethylating agents (HMAs), have been a mainstay in the treatment of higher-risk myelodysplastic syndromes. The development of oral HMAs has been an area of active interest; however, oral bioavailability has been quite poor due to rapid metabolism by cytidine deaminase (CDA). This led to the development of the novel CDA inhibitor cedazuridine, which was combined with an oral formulation of decitabine. Preclinical work demonstrated a pharmacokinetic and pharmacodynamic profile approximate to parenteral decitabine, leading to early-phase clinical trials of oral cedazuridine-decitabine (C-DEC) in myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML). A combination of oral decitabine 35 mg with oral cedazuridine 100 mg was established as the recommended phase 2 dose. Phase 2 data confirmed bioequivalence of C-DEC when compared with parenteral decitabine, and a larger phase 3 trial has demonstrated similar results, leading to the FDA approval of C-DEC for use in intermediate/high-risk myelodysplastic syndrome (MDS) and CMML. This review will focus upon the current role of HMA therapy in MDS/CMML, preclinical and clinical development of C-DEC, and potential roles of oral HMA therapy in myeloid malignancies moving forward.
引用
- Patel AA, Cahill K, Saygin C, et al. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021. PMID: 33904891. doi:10.1182/bloodadvances.2020002929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。